Altasciences has completed an expansion of its research and development laboratory at its drug product formulation and manufacturing facility in Harleysville, Pennsylvania, adding about 768 square feet of new lab space. The square footage itself is modest. What the company is actually selling with this expansion is something bigger: the idea that in contract drug development, being the most connected partner matters more than being the biggest one.
What Actually Changed at the Facility
The expansion brings formulation development and analytical testing into a single integrated lab environment at the Harleysville site, rather than keeping those functions siloed. In practice, that means the facility can now run phase-appropriate, target product profile-driven formulation screening for small molecules, peptides, and more complex modalities, alongside non-GLP and GLP toxicology sample support for nonclinical studies, advanced screening models, and integrated analytical testing, all under one roof. Because the R&D side operates in a non-GLP environment, clients get room to design and optimize a formulation before it moves into the more rigid, regulated study phase, which is typically where costly rework gets discovered too late.
Anuji Abraham, Altasciences’ Senior Director of Pharmaceutical Development, framed the point of the expansion around timing rather than square footage: “With this expansion, we are strengthening our focus on early-stage integration, bringing our CDMO capabilities to clients earlier in the drug development journey.” Robert Sabelli, the company’s Co-Chief Operating Officer, tied it to talent as much as infrastructure: “By continuing to invest in our team, we are growing our scientific talent and connecting our capabilities earlier in the development cycle.”
The Bigger Argument Altasciences Is Making
Julie-Ann Cabana, Altasciences’ Chief Marketing Officer, laid out the thinking behind moves like this one in comments tied to the announcement, and it’s worth reading directly because it’s a clearer statement of strategy than the press release itself: “The future of drug development won’t be defined by who offers the most services. It will be defined by who connects them best and offers the simplest and fastest outsourcing solution.” Her argument is that biotech and pharma clients aren’t actually asking for more vendors or more service menus, they’re asking for fewer handoffs between manufacturing, nonclinical, and clinical development, since every handoff is a place where a program can lose weeks or months.
That’s the case for why Harleysville got this specific upgrade rather than just more capacity somewhere else in the network. Cabana described the expansion as one piece of a much larger pattern of investment at Altasciences, alongside growth in its bioanalytical network and manufacturing capabilities, all aimed at building what she called “the industry’s most connected early-phase drug development organization.” The underlying math she’s pointing to is straightforward: in early drug development, a month saved on formulation or nonclinical readiness can be worth millions of dollars in preserved value and, more importantly, real time back for patients waiting on a therapy to reach them.
Why This Fits the Region
Harleysville sits in Montgomery County, part of the broader Greater Philadelphia life sciences corridor, and this expansion adds to a growing list of CDMO and drug development infrastructure investment happening in that area. Altasciences itself is headquartered in Laval, Québec, and operates as a full-service CRO/CDMO with more than 30 years in the business, but the fact that one of its integration bets is landing at a Pennsylvania site says something about where the company sees demand concentrated. Whether “most connected” ends up being the winning pitch in a crowded CDMO market remains to be seen, but Altasciences is clearly willing to put lab space, scientific hires, and marketing behind the argument that fewer seams, not more services, is what actually gets a drug from lead candidate to clinical proof of concept faster.
